Theratechnologies http://www.theratech.com/ Theratechnologies develops therapies for unmet medical needs in commercially attractive specialty markets. en-ca Copyright 2006 daily Theratechnologies presents combined Phase 3 clinical results at European AIDS Conference http://feedproxy.google.com/~r/Theratechnologies_news/~3/wNHjX2pZbls/news.php Montréal, Canada - November 11, 2009 - Theratechnologies (TSX: TH) announced today that results from a pooled analysis from both its Phase 3 clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy were presented as a poster (Poster number: #BPD2/1) at the 12th European AIDS Conference/EACS in Cologne, Germany. This Poster will also be presented as part of a "Best Poster" discussion on Friday. In addition, as part of its disease awareness program, Theratechnologies will also sponsor a symposium entitled "Lipohypertrophy: Beyond Body Image", which will be held tomorrow morning at the Conference. The poster outlined pooled data from both Phase 3 clinical trials and demonstrated that treatment with 2 mg tesamorelin daily for 26 weeks resulted in: Significant visceral adipose tissue ("VAT") decrease in tesamorelin-treated patients after 26 weeks of treatment (-13.1±21.1% p<0.001 vs. placebo); No clinically significant changes in limb fat (0.2±13.2%, p=0.001 vs. placebo) and in abdominal subcutaneous adipose tissue ("SAT") (0.7±15.5%, p=0.08 vs. placebo); Significant decrease in triglycerides (-0.4±1.6 mmol/L, p<0.001 vs. placebo). At Week 52, improvements in VAT and triglycerides observed at Week 26 were sustained in the group of patients who received tesamorelin over 52 weeks (-17.5±23.3% and -0.5±2.0 mmol/L, respectively, p<0.001 vs. baseline). Patients who were switched from tesamorelin to placebo treatment at Week 26, per the study design, regained VAT at Week 52 (0.3±26.3%, p=0.18 vs. baseline). No clinically important changes in glucose parameters were observed after treatment with tesamorelin at both Weeks 26 and 52. The poster presented is now available on Theratechnologies' website at http://www.theratech.com/ About HIV-Associated LipodystrophySeveral factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence.About Theratechnologies Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone-releasing factor. In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV-infected patients with lipodystrophy. In addition, the Company signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions.Forward-Looking Information This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding the growth of Theratechnologies through the development of tesamorelin and additional clinical programs. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the variations of them denote forward-looking information.Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the incapacity of Theratechnologies to further develop tesamorelin as a result of serious adverse events related to its administration or non-conclusive results from additional development programs. The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http://www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law. Montréal, Canada - November 11, 2009 - Theratechnologies (TSX: TH) announced today that results from a pooled analysis from both its Phase 3 clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy were presented as a poster (Poster number: #BPD2/1) at the 12th European AIDS Conference/EACS in Cologne, Germany. This Poster will also be presented as part of a "Best Poster" discussion on Friday. In addition, as part of its disease awareness program, Theratechnologies will also sponsor a symposium entitled "Lipohypertrophy: Beyond Body Image", which will be held tomorrow morning at the Conference.

The poster outlined pooled data from both Phase 3 clinical trials and demonstrated that treatment with 2 mg tesamorelin daily for 26 weeks resulted in:

  • Significant visceral adipose tissue ("VAT") decrease in tesamorelin-treated patients after 26 weeks of treatment (-13.1±21.1% p<0.001 vs. placebo);
  • No clinically significant changes in limb fat (0.2±13.2%, p=0.001 vs. placebo) and in abdominal subcutaneous adipose tissue ("SAT") (0.7±15.5%, p=0.08 vs. placebo);
  • Significant decrease in triglycerides (-0.4±1.6 mmol/L, p<0.001 vs. placebo).

At Week 52, improvements in VAT and triglycerides observed at Week 26 were sustained in the group of patients who received tesamorelin over 52 weeks (-17.5±23.3% and -0.5±2.0 mmol/L, respectively, p<0.001 vs. baseline). Patients who were switched from tesamorelin to placebo treatment at Week 26, per the study design, regained VAT at Week 52 (0.3±26.3%, p=0.18 vs. baseline). No clinically important changes in glucose parameters were observed after treatment with tesamorelin at both Weeks 26 and 52.

The poster presented is now available on Theratechnologies' website at http://www.theratech.com/

About HIV-Associated Lipodystrophy
Several factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone-releasing factor.

In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV-infected patients with lipodystrophy. In addition, the Company signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions.

Forward-Looking Information
This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding the growth of Theratechnologies through the development of tesamorelin and additional clinical programs. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the variations of them denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the incapacity of Theratechnologies to further develop tesamorelin as a result of serious adverse events related to its administration or non-conclusive results from additional development programs. The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http://www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

]]> Theratechnologies presents combined Phase 3 clinical results at European AIDS Conference 2009-11-11 http://www.theratech.com/en/news-events/news.php?id=359 Theratechnologies’ NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee http://feedproxy.google.com/~r/Theratechnologies_news/~3/YbMY8AEh1CQ/news.php Montreal, Canada - November 5, 2009 - Theratechnologies (TSX:TH) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration ("FDA") will review Theratechnologies' NDA for tesamorelin in the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The role of the Advisory Committee, which is tentatively scheduled to meet with Theratechnologies during the first quarter of 2010, is to provide the FDA with independent opinions on the use of tesamorelin from medical experts, patient groups and various stakeholders. "We view the solicitation of additional viewpoints from various external groups as positive and over the next few months we will work together with the FDA to prepare for the meeting," noted Mr. Yves Rosconi, President and Chief Executive Officer of Theratechnologies.  As part of the FDA review process, the primary role of an Advisory Committee is to provide independent advice that will contribute to the quality of the agency's regulatory decision-making process. In the situation where a first-of-a-kind medical product, like tesamorelin, is evaluated for human use, it is common procedure to refer such a drug to an Advisory Committee prior to making a decision as stated in the FDA regulations. Although Advisory Committees provide their opinions to the Agency during publicly held meetings, the final decisions on marketing approvals are made by FDA.Theratechnologies submitted an NDA to the FDA on May 29, 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.  The FDA filed the NDA on August 12, 2009, which initiated a substantive review of the application. About HIV-Associated LipodystrophySeveral factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients.About TheratechnologiesTheratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor. In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions. Montreal, Canada - November 5, 2009 - Theratechnologies (TSX:TH) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration ("FDA") will review Theratechnologies' NDA for tesamorelin in the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The role of the Advisory Committee, which is tentatively scheduled to meet with Theratechnologies during the first quarter of 2010, is to provide the FDA with independent opinions on the use of tesamorelin from medical experts, patient groups and various stakeholders.

"We view the solicitation of additional viewpoints from various external groups as positive and over the next few months we will work together with the FDA to prepare for the meeting," noted Mr. Yves Rosconi, President and Chief Executive Officer of Theratechnologies. 

As part of the FDA review process, the primary role of an Advisory Committee is to provide independent advice that will contribute to the quality of the agency's regulatory decision-making process. In the situation where a first-of-a-kind medical product, like tesamorelin, is evaluated for human use, it is common procedure to refer such a drug to an Advisory Committee prior to making a decision as stated in the FDA regulations. Although Advisory Committees provide their opinions to the Agency during publicly held meetings, the final decisions on marketing approvals are made by FDA.

Theratechnologies submitted an NDA to the FDA on May 29, 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.  The FDA filed the NDA on August 12, 2009, which initiated a substantive review of the application.

About HIV-Associated Lipodystrophy
Several factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions.

]]> Theratechnologies’ NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee 2009-11-05 http://www.theratech.com/en/news-events/news.php?id=358 Theratechnologies presents clinically relevant improvements in patient reported outcome parameters http://feedproxy.google.com/~r/Theratechnologies_news/~3/GU56RdR2I3A/news.php  Theratechnologies presents clinically relevant improvements in patient reported outcome parameters at the International Workshop on Adverse Drug Reactions and Co-morbidities in HIVMontreal, Canada - October 26, 2009 - Theratechnologies (TSX :TH) announced today that additional patient reported outcome results from a combined analysis from both Phase 3 clinical trials evaluating tesamorelin in the treatment of excess abdominal fat in HIV- infected patients with lipodystrophy, were presented today at the 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV, in Philadelphia, USA. The data presented today is part of the New Drug Application ("NDA") submitted by Theratechnologies to the US Food and Drug Administration ("FDA") at the end of May 2009. Dr. Ralph Turner, Vice President, Phase V Technologies, Inc., presented combined analysis results from the main phase of Theratechnologies' two Phase 3 clinical trials and reviewed the impact of tesamorelin on belly and weight image and on health-related quality of life ("HRQOL") parameters. Self-perceived body image, an important secondary endpoint, was determined by a validated questionnaire developed by Phase V Technologies, Inc. The results indicated that after 26 weeks of treatment the 543 patients treated with 2 mg daily of tesamorelin reported clinically relevant improvements in belly appearance distress, as well as in belly and weight image while maintaining HRQOL, with no increases in symptom incidence and distress. Moreover, the decrease in visceral adipose tissue ("VAT") observed in tesamorelin treated patients was correlated with various improvements in patient reported outcome parameters.Summary of AbstractPatients treated with tesamorelin reported significantly less belly appearance distress than patients on placebo (Week 26 change from baseline: 9.8±28.0 vs. 5.9±25.8, p=0.002) and patient- and physician-reported belly profile improved significantly more in tesamorelin than placebo treated patients (-0.6±1.3 vs. -0.3±1.1, p=0.003 and -0.6±1.1 vs. -0.3±1.1, p<0.001, respectively). Significant improvements were also observed in tesamorelin-treated patients for the evaluation of weight concern and current appearance distress (-7.2±25.0 vs. -2.5±28.7, p=0.014 and 0.8±1.7 vs. 0.4±1.5, p<0.001, respectively). Global HRQOL significantly deteriorated in placebo patients (-0.2±1.5) compared to tesamorelin-treated patients, who maintained their HRQOL (0.0±1.5, p=0.029 vs. placebo). Tesamorelin-treated patients improved significantly versus baseline for symptoms and side effects incidence (17.4±69.0, p<0.001), and no significant differences versus baseline or placebo were observed for symptoms and side effects distress (2.9±38.5 vs. -0.3±40.8, for tesamorelin vs. placebo, p=0.204). The responsiveness unit analysis revealed clinically important effects (effect size≥0.15) in tesamorelin-treated patients for belly appearance, patient- and physician-reported belly profile and each of the weight image endpoints. In contrast, there was a clinically meaningful deterioration in these patient reported outcome parameters in the placebo group. Changes in body image and HRQOL parameters were significantly correlated with changes in VAT (p<0.05) for tesamorelin-treated patients, whereas no correlations were observed in placebo-treated patients.About HIV-Associated LipodystrophySeveral factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence. Phase V TechnologiesPhase V's clinical and outcomes research services include strategic planning, design, conduct, evaluation, and analysis of clinical trials. As part of new drug and device development the Phase V® Outcomes Research System focuses on evaluating the effectiveness and acceptance of new therapies from the patient and health economic perspective. About Theratechnologies Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone-releasing factor. With a New Drug Application ("NDA") recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.Forward-Looking Information This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding the growth of Theratechnologies through the development of tesamorelin and additional clinical programs. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the variations of them denote forward-looking information. Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the incapacity of Theratechnologies to further develop tesamorelin as a result of serious adverse events related to its administration or non-conclusive results from additional development programs. The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http://www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.  Theratechnologies presents clinically relevant improvements in patient reported outcome parameters at the International Workshop on Adverse Drug Reactions and Co-morbidities in HIV

Montreal, Canada - October 26, 2009 - Theratechnologies (TSX :TH) announced today that additional patient reported outcome results from a combined analysis from both Phase 3 clinical trials evaluating tesamorelin in the treatment of excess abdominal fat in HIV- infected patients with lipodystrophy, were presented today at the 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV, in Philadelphia, USA. The data presented today is part of the New Drug Application ("NDA") submitted by Theratechnologies to the US Food and Drug Administration ("FDA") at the end of May 2009.

Dr. Ralph Turner, Vice President, Phase V Technologies, Inc., presented combined analysis results from the main phase of Theratechnologies' two Phase 3 clinical trials and reviewed the impact of tesamorelin on belly and weight image and on health-related quality of life ("HRQOL") parameters. Self-perceived body image, an important secondary endpoint, was determined by a validated questionnaire developed by Phase V Technologies, Inc. The results indicated that after 26 weeks of treatment the 543 patients treated with 2 mg daily of tesamorelin reported clinically relevant improvements in belly appearance distress, as well as in belly and weight image while maintaining HRQOL, with no increases in symptom incidence and distress. Moreover, the decrease in visceral adipose tissue ("VAT") observed in tesamorelin treated patients was correlated with various improvements in patient reported outcome parameters.

Summary of Abstract
Patients treated with tesamorelin reported significantly less belly appearance distress than patients on placebo (Week 26 change from baseline: 9.8±28.0 vs. 5.9±25.8, p=0.002) and patient- and physician-reported belly profile improved significantly more in tesamorelin than placebo treated patients (-0.6±1.3 vs. -0.3±1.1, p=0.003 and -0.6±1.1 vs. -0.3±1.1, p<0.001, respectively). Significant improvements were also observed in tesamorelin-treated patients for the evaluation of weight concern and current appearance distress (-7.2±25.0 vs. -2.5±28.7, p=0.014 and 0.8±1.7 vs. 0.4±1.5, p<0.001, respectively). Global HRQOL significantly deteriorated in placebo patients (-0.2±1.5) compared to tesamorelin-treated patients, who maintained their HRQOL (0.0±1.5, p=0.029 vs. placebo). Tesamorelin-treated patients improved significantly versus baseline for symptoms and side effects incidence (17.4±69.0, p<0.001), and no significant differences versus baseline or placebo were observed for symptoms and side effects distress (2.9±38.5 vs. -0.3±40.8, for tesamorelin vs. placebo, p=0.204).

The responsiveness unit analysis revealed clinically important effects (effect size≥0.15) in tesamorelin-treated patients for belly appearance, patient- and physician-reported belly profile and each of the weight image endpoints. In contrast, there was a clinically meaningful deterioration in these patient reported outcome parameters in the placebo group. Changes in body image and HRQOL parameters were significantly correlated with changes in VAT (p<0.05) for tesamorelin-treated patients, whereas no correlations were observed in placebo-treated patients.

About HIV-Associated Lipodystrophy
Several factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence.

Phase V Technologies
Phase V's clinical and outcomes research services include strategic planning, design, conduct, evaluation, and analysis of clinical trials. As part of new drug and device development the Phase V® Outcomes Research System focuses on evaluating the effectiveness and acceptance of new therapies from the patient and health economic perspective.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone-releasing factor.

With a New Drug Application ("NDA") recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.

Forward-Looking Information
This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding the growth of Theratechnologies through the development of tesamorelin and additional clinical programs. Words such as "will", "may", "could", "should", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the variations of them denote forward-looking information.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: the incapacity of Theratechnologies to further develop tesamorelin as a result of serious adverse events related to its administration or non-conclusive results from additional development programs.

The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 24, 2009. The AIF is available at http://www.sedar.com/ under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.

Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date. The Company does not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

]]> Theratechnologies presents clinically relevant improvements in patient reported outcome parameters 2009-10-26 http://www.theratech.com/en/news-events/news.php?id=357 Theratechnologies to present at BioContact Québec http://feedproxy.google.com/~r/Theratechnologies_news/~3/M1UO5xl2vAM/news.php Montréal, October 6, 2009 - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will be presenting an overview of Theratechnologies at BioContact Québec, which will take place at the Château Frontenac, in Québec City.  At his presentation on Thursday, October 8 at 3:00 p.m., Mr. Rosconi will review the operational accomplishments over the last year and discuss Theratechnologies' strategy and growth opportunities. BioContact Québec is a biopharmaceutical partnership symposium attended by over 1,000 participants. About TheratechnologiesTheratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor. In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions. Montréal, October 6, 2009 - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will be presenting an overview of Theratechnologies at BioContact Québec, which will take place at the Château Frontenac, in Québec City.  At his presentation on Thursday, October 8 at 3:00 p.m., Mr. Rosconi will review the operational accomplishments over the last year and discuss Theratechnologies' strategy and growth opportunities. BioContact Québec is a biopharmaceutical partnership symposium attended by over 1,000 participants.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.]]> Theratechnologies to present at BioContact Québec 2009-10-06 http://www.theratech.com/en/news-events/news.php?id=356 Theratechnologies Announces Financial Results for the Third Quarter 2009 http://feedproxy.google.com/~r/Theratechnologies_news/~3/z0zd6WlhN-c/news.php Theratechnologies Announces Financial Results for the Third Quarter 2009 2009-10-05 http://www.theratech.com/en/news-events/news.php?id=355 Theratechnologies to present at UBS Global Life Sciences Conference http://feedproxy.google.com/~r/Theratechnologies_news/~3/1_fK36p_CPE/news.php Montréal, Canada, September 21, 2009 -  Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer, will present an overview of the Company, on Wednesday, September 23, at 12:30 p.m., at the 2009 UBS Global Life Sciences Conference which will take place at the Grand Hyatt in New York City. At this occasion, Mr. Rosconi will discuss how the Company is well positioned with a business plan built on an advanced compound and a solid balance sheet making Theratechnologies a leader in the Canadian biotech industry. About TheratechnologiesTheratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor. In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. The Company also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions. Montréal, Canada, September 21, 2009 -  Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer, will present an overview of the Company, on Wednesday, September 23, at 12:30 p.m., at the 2009 UBS Global Life Sciences Conference which will take place at the Grand Hyatt in New York City. At this occasion, Mr. Rosconi will discuss how the Company is well positioned with a business plan built on an advanced compound and a solid balance sheet making Theratechnologies a leader in the Canadian biotech industry.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. The Company also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.]]> Theratechnologies to present at UBS Global Life Sciences Conference 2009-09-21 http://www.theratech.com/en/news-events/news.php?id=354 Theratechnologies to receive a milestone payment of US $10 million associated with the FDA acceptance to file tesamorelin NDA http://feedproxy.google.com/~r/Theratechnologies_news/~3/mPi3P8XWlGI/news.php Montreal, Canada - August 12, 2009 - Theratechnologies (TSX:TH) today announced that the US Food and Drug Administration ("FDA") has accepted to file the New Drug Application ("NDA") made by the Company for its lead compound, tesamorelin. Under the terms of the Company's collaboration and licensing agreement with EMD Serono, Inc., the acceptance to file tesamorelin NDA is associated with a milestone payment of US $10 million (approximately CAN $11 million). Theratechnologies submitted an NDA to the FDA on May 29, 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy. The acceptance to file the NDA means that FDA will now begin its substantive review of the application. About HIV-Associated LipodystrophySeveral factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients.About TheratechnologiesTheratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor. In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions. Montreal, Canada - August 12, 2009 - Theratechnologies (TSX:TH) today announced that the US Food and Drug Administration ("FDA") has accepted to file the New Drug Application ("NDA") made by the Company for its lead compound, tesamorelin. Under the terms of the Company's collaboration and licensing agreement with EMD Serono, Inc., the acceptance to file tesamorelin NDA is associated with a milestone payment of US $10 million (approximately CAN $11 million).

Theratechnologies submitted an NDA to the FDA on May 29, 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy. The acceptance to file the NDA means that FDA will now begin its substantive review of the application.

About HIV-Associated Lipodystrophy
Several factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.

]]> Theratechnologies to receive a milestone payment of US $10 million associated with the FDA acceptance to file tesamorelin NDA 2009-08-12 http://www.theratech.com/en/news-events/news.php?id=353 Theratechnologies to present at both BMO and Canaccord Adams Conferences http://feedproxy.google.com/~r/Theratechnologies_news/~3/p3_Z5qawaow/news.php Montréal, Canada - August 3, 2009 - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will present corporate overviews at both the BMO Capital Markets Focus on Healthcare Conference and the 29th Annual Canaccord Adams Global Growth Conference. The BMO presentation will take place on August 5, at 10:45 a.m., at the Millennium Broadway Hotel in New York City and the Canaccord Adams presentation, on August 13, at 11:00 a.m., at the InterContinental in Boston. About TheratechnologiesTheratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor. In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions. Montréal, Canada - August 3, 2009 - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will present corporate overviews at both the BMO Capital Markets Focus on Healthcare Conference and the 29th Annual Canaccord Adams Global Growth Conference.

The BMO presentation will take place on August 5, at 10:45 a.m., at the Millennium Broadway Hotel in New York City and the Canaccord Adams presentation, on August 13, at 11:00 a.m., at the InterContinental in Boston.

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.

]]> Theratechnologies to present at both BMO and Canaccord Adams Conferences 2009-08-03 http://www.theratech.com/en/news-events/news.php?id=352 Theratechnologies Announces Financial Results and Highlightsfor the Second Quarter 2009 http://feedproxy.google.com/~r/Theratechnologies_news/~3/5Kz4Pp8ZJfg/news.php Theratechnologies Announces Financial Results and Highlightsfor the Second Quarter 2009 2009-07-07 http://www.theratech.com/en/news-events/news.php?id=351 Theratechnologies awarded Le Prix Santé by the Fondation Armand-Frappier http://feedproxy.google.com/~r/Theratechnologies_news/~3/ZY2-d6fXGiU/news.php Montréal, Canada - June 19, 2009 - Theratechnologies (TSX: TH) is proud to announce that it was awarded the Fondation Armand-Frappier's Prix Santé 2009 at the 16th annual Fête Champêtre held last evening on the campus of  the INRS-Institut Armand-Frappier in Laval. "It's an honour for Theratechnologies to receive this prestigious prize", said Yves Rosconi, the Company's President and Chief Executive Officer.  "As genuine recognition by our peers, this prize pays tribute to the work and dedication of a team that was able to successfully complete a clinical program for tesamorelin, a molecule discovered in-house, file for marketing approval with the American regulatory authorities and join forces with an ideal partner for its commercialization in the United States", he added.  "I would like to thank all of Theratechnologies' employees who, through their efforts, contributed to the achievement of our business-plan objectives, as well as our shareholders for their loyal support and patience", Mr. Rosconi concluded. Awarded by the Fondation Armand-Frappier on the recommendation of its scientific committee, Le Prix Santé recognizes success by Québec companies in the human health, animal health, environmental and agro-food fields.  In order to qualify, companies must have conceived, developed and commercialized a scientific innovation, or be about to do so.In 1998, Theratechnologies received Le Prix Émergence from the Fondation Armand-Frappier in recognition of its notable contribution to research and development in Québec.About the Fondation Armand-FrappierThe Fondation Armand-Frappier is a non-profit organization that encourages excellence in the training of the next generation of scientists and the advancement of health research in its areas of interest.  Since its inception in 1978, the Fondation has distributed more than $8 million in the form of scholarships, research chairs, equipment purchases or contributions to scientific projects.  The Fête Champêtre, a true celebration of healthcare research, is the high point of its fund-raising activities and is considered a not-to-be-missed occasion by the business and life-science milieus.  About TheratechnologiesTheratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor. In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs. Montréal, Canada - June 19, 2009 - Theratechnologies (TSX: TH) is proud to announce that it was awarded the Fondation Armand-Frappier's Prix Santé 2009 at the 16th annual Fête Champêtre held last evening on the campus of  the INRS-Institut Armand-Frappier in Laval.

"It's an honour for Theratechnologies to receive this prestigious prize", said Yves Rosconi, the Company's President and Chief Executive Officer.  "As genuine recognition by our peers, this prize pays tribute to the work and dedication of a team that was able to successfully complete a clinical program for tesamorelin, a molecule discovered in-house, file for marketing approval with the American regulatory authorities and join forces with an ideal partner for its commercialization in the United States", he added.  "I would like to thank all of Theratechnologies' employees who, through their efforts, contributed to the achievement of our business-plan objectives, as well as our shareholders for their loyal support and patience", Mr. Rosconi concluded.

Awarded by the Fondation Armand-Frappier on the recommendation of its scientific committee, Le Prix Santé recognizes success by Québec companies in the human health, animal health, environmental and agro-food fields.  In order to qualify, companies must have conceived, developed and commercialized a scientific innovation, or be about to do so.

In 1998, Theratechnologies received Le Prix Émergence from the Fondation Armand-Frappier in recognition of its notable contribution to research and development in Québec.

About the Fondation Armand-Frappier
The Fondation Armand-Frappier is a non-profit organization that encourages excellence in the training of the next generation of scientists and the advancement of health research in its areas of interest.  Since its inception in 1978, the Fondation has distributed more than $8 million in the form of scholarships, research chairs, equipment purchases or contributions to scientific projects.  The Fête Champêtre, a true celebration of healthcare research, is the high point of its fund-raising activities and is considered a not-to-be-missed occasion by the business and life-science milieus. 

About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor.

In 2008, Theratechnologies completed its Phase 3 clinical program evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application recently filed with the US authorities, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin, in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

]]> Theratechnologies awarded Le Prix Santé by the Fondation Armand-Frappier 2009-06-19 http://www.theratech.com/en/news-events/news.php?id=350